Last $35.21 USD
Change Today -1.46 / -3.98%
Volume 263.4K
EPZM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:30 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

epizyme inc (EPZM) Snapshot

Open
$36.46
Previous Close
$36.67
Day High
$36.50
Day Low
$34.87
52 Week High
10/1/13 - $42.71
52 Week Low
11/14/13 - $18.10
Market Cap
1.2B
Average Volume 10 Days
500.2K
EPS TTM
$-0.44
Shares Outstanding
33.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPIZYME INC (EPZM)

epizyme inc (EPZM) Related Businessweek News

No Related Businessweek News Found

epizyme inc (EPZM) Details

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors. The company has therapeutic collaborations with Celgene Corporation and Celgene International Sàrl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

74 Employees
Last Reported Date: 02/28/14
Founded in 2007

epizyme inc (EPZM) Top Compensated Officers

Chief Executive Officer, Secretary and Direct...
Total Annual Compensation: $564.7K
President, Chief Financial Officer, Principal...
Total Annual Compensation: $513.2K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $487.5K
Chief Medical Officer
Total Annual Compensation: $463.5K
Compensation as of Fiscal Year 2013.

epizyme inc (EPZM) Key Developments

Epizyme, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of 2014

Epizyme, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported collaboration revenue of $9,494,000 against $14,839,000 a year ago. Loss from operations was $13,311,000 against $2,177,000 a year ago. Loss allocable to common stockholders was $13,386,000 or $0.40 per basic and diluted share against $2,319,000 or $0.25 per basic and diluted share a year ago. For the six months, the company reported collaboration revenue of $22,885,000 against $23,721,000 a year ago. Loss from operations was $20,223,000 against $9,654,000 a year ago. Loss allocable to common stockholders was $20,270,000 or $0.63 per basic and diluted share against $9,973,000 or $1.82 per basic and diluted share a year ago. The company provided cash flow guidance for the full year 2014. The company continues to expect full-year 2014 net cash used in operating activities to be approximately $50 million, including $34 million in accounts receivable recorded in 2013 but collected in 2014. Excluding these accounts receivable, adjusted net cash used in operating activities in 2014 is expected to be approximately $80 million. The company expects to end 2014 with more than $170 million in cash and cash equivalents, which is expected to fund the company until at least mid-2016, prior to including any potential future milestone payments.

Epizyme Announces Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology

Epizyme, Inc. reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas. These data were presented by Robert Copeland, Ph.D., Chief Scientific Officer, Epizyme, during an oral session on novel therapeutics in lymphoma at the American Society of Hematology (ASH) meeting on Lymphoma Biology, held August 10-13 in Colorado Springs, Colorado. Pre-clinical data have shown the utility of single-agent EZH2 inhibitors in both EZH2 mutant and EZH2 wild type germinal center (GC) NHL models. Data presented showed that in pre-clinical studies in GC NHL cell lines, combining EPZ-6438 with CHOP, a chemotherapy cocktail regimen that is a standard of care in NHL, resulted in strong synergy of lymphoma cell killing. When EPZ-6438 was combined with each individual component of the CHOP regimen, the synergy was great with prednisone, the corticosteroid component of CHOP. Prednisone greatly enhanced the potency of EPZ-6438 for killing EZH2 mutant-bearing lymphoma cell lines, and broadened the activity of EPZ-6438 to all GC NHL cell lines, regardless of EZH2 mutational status. Combining EPZ-6438 with dexamethasone, another corticosteroid, yielded similar synergistic results. Synergy was also observed in both EZH2 mutant and wild type cell lines when EPZ-6438 was combined with B-cell signaling pathway agents and BCL2 antagonists. The primary objective of the ongoing Phase 1 dose escalation study is to evaluate the safety and tolerability of EPZ-6438 and determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D); the secondary objectives are to determine pharmacokinetics (PK) and pharmacodynamics (PD) of EPZ-6438. The study to date consists of five dosing cohorts, with evaluation of doses of 100 mg to 1600 mg BID, orally administered in 28-day cycles without a drug holiday in patients with advanced solid tumors or with relapsed or refractory B-cell lymphoma. Three of five dosing cohorts (100, 200 and 400 mg) have been completed with 12 evaluable patients dosed, four of whom were NHL patients. Dose cohorts evaluating 800 mg and 1600 mg are ongoing. Early clinical observations from the three completed cohorts include: MTD has not been reached; there were no DLTs or AE-related treatment discontinuations. PK was dose-proportional across these three cohorts. PD evidence of target inhibition was observed in skin. Two NHL patients achieved objective responses: a partial response in a patient with relapsed transformed diffuse large B-cell lymphoma (DLBCL), and an ongoing partial response in a patient with primary refractory mediastinal B-cell lymphoma (PMBCL). Additionally, a patient with follicular lymphoma with EZH2 mutation had stable disease.

Epizyme, Inc. to Report Q2, 2014 Results on Aug 13, 2014

Epizyme, Inc. announced that they will report Q2, 2014 results on Aug 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $35.21 USD -1.46

EPZM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EPZM.
View Industry Companies
 

Industry Analysis

EPZM

Industry Average

Valuation EPZM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.0x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.